Prelude Therapeutics Q1 2026 Earnings Significant EPS Beat Amid No Revenue TOI Q1 2026 Earnings Strong Earnings Beat Amidst Limited Revenue Disclosure MATV Q1 2026 Earnings Significant EPS Beat Amid Cost Discipline and Strategic Focus BJRI Q1 2026 Earnings Earnings Miss Estimates Amid Mixed Results EFOI Q4 2024 Earnings Narrowed Loss Highlights Ongoing Restructuring Efforts REAX Q1 2026 Earnings NarrowerThanExpected Loss Fails to Move Shares